Home
Vertex Pharmaceuticals Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults with IgA Nephropathy

Vertex Pharmaceuticals Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults with IgA Nephropathy

Today’s Highlights March 9, 2026

Vertex Pharmaceuticals in the NEWS

March 9, 2026, Vertex Pharmaceuticals (VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN).

The trial . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
March 9, 2026

Other Articles